Canaccord Genuity Maintains Buy on Definium Therapeutics, Lowers Price Target to $58

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ: DFTX ) with a Buy and lowers the price target from $60 to $58.